Tenderwize
Retour à la recherche

Open-house biologics rebate agreement for Epoetin beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 522 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-39 - Epoetin beta

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

The notice contains two different end-time references: structured data gives 2028-01-30 22:59:59 UTC, while the XML not...

Participation is limited to pharmaceutical undertakings meeting the AMG and authorisation conditions for the specific p...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Supply-related pharmaceutical rebate agreement for Epoetin beta.
  • Open-house arrangement with uniform contractual conditions for all eligible participants.
Afficher le résumé complet

Open-house pharmaceutical supply arrangement for Epoetin beta in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical undertaking may join during the contract period, subject to the stated legal and self-declaration requirements. No contract value is provided. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents are only available electronically. The notice is in German and the extracted TED XML notice was analyzed, but no separate procurement document text was provided.

Risques

The notice contains two different end-time references: structured data gives 2028-01-30 22:59:59 UTC, while the XML not...

Participation is limited to pharmaceutical undertakings meeting the AMG and authorisation conditions for the specific p...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-house biologics rebate agreement for Epoetin beta

Open-house contract for pharmaceutical rebate agreements under Section 130c(1) SGB V for the active substance Epoetin beta. The lot covers nationwide performance in Germany and is described as an open-house procedure with uniform conditions, no individual negotiations, and no exclusivity. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 30, 2028

Détails de la procédure

Date de publication
03 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
803675-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3